Abstract. A parallel study design with a large number of subjects has been a typical path for pharmacokinetic (PK) biocomparability assessment of biotherapeutics with long half-lives and immunogenic propensity, for example, monoclonal antibodies (mAb). A recently published innovative bioanalytical method that can quantify mAb produced from two different cell lines in the same sample opened an avenue to exploring a simultaneous crossover study design for PK biocomparability assessment of biotherapeutics. Siltuximab, a chimeric IgG1 mAb-targeting interleukin-6, was studied as an example. The pharmacokinetic biocomparability of siltuximab derived from mouse myeloma (Sp2/0) cells and Chinese hamster ovary cells was previously assessed and demonstrated in a clinical PK biocomparability study that enrolled more than 140 healthy subjects using a parallel trial design. The biocomparability was successfully shown in six cynomolgus monkeys in a preclinical proof-of-concept study using the new crossover study design supported by the analytical method. The impact of antidrug antibodies on the assessment of biocomparability was minimal. This novel approach opened up a new arena for the evaluation of PK biocomparability of biotherapeutics with unique molecular signatures such as a mAb derived from different cell lines.
INTRODUCTION
The US FDA guidance (1) published in 1996 has outlined its perspectives on bioequivalence or biocomparability. Similar requirements can be found in the European Medicines Agency's (EMA) guideline documents (2) and those from most other regulatory agencies (3) . In order to establish the pharmacokinetic (PK) biocomparability for biologic products, most investigators followed the FDA guidances of 1992 (4) and 2001 (5) to show that the 90% confidence intervals (CI) of the ratios of the major PK parameters such as the maximum concentration (C max ) and area under the concentration-time curve (AUC) of the test article to the reference fall between 80% and 125%. Proper sample size selection based on the study design and accuracy of variability estimates is essential for a study to have the 80% or 90% power (5) . Incorporation of pharmacodynamic markers and efficacy data in addition to PK for biocomparability criteria is also discussed recently (6) for biologics.
Crossover study design was recommended by the FDA for its statistical superiority (5). The design was also proposed for biologic products (7) and had been applied for those therapeutics with relatively short half-lives (t 1/2 ) (8,9). Nonetheless, there are significant challenges in conducting a PK biocomparability study for many biologic products. For example, monoclonal antibodies (mAbs) usually have very long elimination half-lives (in weeks). The potential development of immunogenicity adds another source of variability. Antidrug antibodies (ADA) may develop following even a single-dose administration (10, 11) . The rate of occurrence varies and could be high according to the type of biologic product (12) . There is likely a significant but hard-to-predict impact on the PK in the individual who has developed ADA (13) . ADA that does impact PK will substantially impair the PK biocomparability assessment. These complexities were recognized in the FDA (1) and EMA (2) guidances. Parallel study design, an alternative to address the complexities, requires a larger number of subjects. For example, the PK biocomparability of siltuximab, a chimeric IgG1 mAb targeting interleukin-6 (IL-6), derived from mouse myeloma (Sp2/0) cells and Chinese hamster ovary (CHO) cells was demonstrated in a clinical study that enrolled more than 140 healthy subjects following an intravenous administration using a parallel design (14) . Rivière et al. (15) conducted a PK biocomparability study of omalizumab formulations in a phase 3 clinical trial; data from 155 atopic subjects was used to achieve the desired statistical outcome.
Recently, an innovative two-step bioanalytical assay was successfully developed by Geist et al. (16) . This analytical approach can quantify recombinant mAb produced from two different cell lines in a mixture separately and simultaneously based on their unique signatures of post-translational glycosylation. This innovation opens an a v en u e f o r e x p l o r i n g a ne w a p p r o a c h to P K biocomparability assessment. A new study design to test the biocomparability of siltuximab derived from the two different cell lines and the results from the study are reported in this brief technical note.
MATERIALS AND METHODS
The preclinical PK comparability study was designed as a simultaneous crossover study in naïve, healthy male cynomolgus monkeys. The animals were 2-5 years old and weighed 2.5-5 kg. The in-life portion of the study was conducted at WuXi AppTec (Suzhou, China). The housing conditions and in-life procedures were approved by the Institutional Animal Care and Use Committees at WuXi AppTec.
Six monkeys received single intravenous injections of CHO-and Sp2/0-derived siltuximab at 2.5 mg/kg each similar to the dose in the clinical study. The sample size was selected as minimally required while still being able to assess experimental variability and provide a good probability to declare comparability based on estimated analytical variance, if the true comparability was between 95% and 105%. For simultaneous crossover, the dose administrations were carried out in two groups with three monkeys randomly assigned into each group. The first group of monkeys received CHO-derived product first, followed by Sp2/0-derived product. The second group received CHO-and Sp2/0-derived products in the reverse order. The two injections were given separately but within 5 min and via the same intravenous (IV) injection port.
Blood samples, from which serum was prepared for PK determination, were collected prior to and up to 35 days following the dose administrations. Total serum concentration of siltuximab (CHO + Sp2/0) was determined using a validated electrochemiluminescence immunoassay method. Siltuximab produced from CHO or Sp2/0 cell lines was equivalently quantified in the immunoassay. The mAb glycosylation analysis was accomplished by immunoaffinity purification followed by reverse-phase liquid chromatography and time-of-flight mass spectrometry detection to determine the ratio of CHO-to Sp2/0-derived products. The total concentration and the ratio were used to calculate siltuximab concentrations origin from each cell line. The details of the assay methodology were described previously (16) .
The PK parameters were calculated using WinNonlin (v5.2.1, Pharsight, Mountain View, CA, USA). The 90% CI was calculated using the WinNonlin Bioequivalence Module. A variance model of cell line + sequence + period for independent variables was used for the evaluation of PK biocomparability. The order of administrations was assigned to sequences, the two IV administrations were assigned to period, and Sp2/0-derived product was used as the reference.
RESULTS
Mean serum concentrations of CHO-and Sp2/0-derived siltuximab were plotted separately in Fig. 1 . Following the administration of CHO-and Sp2/0-derived siltuximab the mean serum concentration-time profiles were superimposable. The C max and AUC t were evaluable in all six (n=6) animals. The ratios (in percent) of the geometric means of C max and AUC t were 106% and 94%, respectively. The 90% CI of the ratios were calculated to be from 98% to 122% for the C max and from 88% to 102% for the AUC t , both within the range of 80% to 125%. The results are summarized in Table I . The results from the comparison of AUC inf were similar (data not shown). Figure 2 shows the individual PK profiles of CHO-and Sp2/0-derived siltuximab in a monkey (T2001) plotted along with the mean profiles from the remaining animals. Siltuximab concentrations exhibited accelerated decrease very similarly for both CHO-and Sp2/0-derived siltuximab in the same animal.
DISCUSSIONS
The PK biocomparability of Sp2/0-and CHO-derived siltuximab was successfully demonstrated in only six animals using a new analytical method and study design, which is in a contrast to the previously reported clinical IV PK biocomparability study (14) in which more than 140 healthy subjects were enrolled. The concept of bolstering the power by minimizing between-treatment variability using our approach is proven in animals, with the understanding that the source and distribution of variability may be different in monkeys and humans. Nonetheless, proper selection of sample size should be based on a full assessment of variability.
The variance attributed to period and sequence was greatly reduced since the administrations of test and reference articles took place virtually simultaneously. Furthermore, enabling paired comparison minimized the impact of µ Fig. 1 . Mean (±SD) siltuximab concentrations (in microgram per milliliter) in the cynomolgus monkey (n=6) following IV administrations of 2.5 mg/kg of CHO-and Sp2/0-derived siltuximab. The concentrations were separately quantified for CHO-or Sp2/0-derived siltuximab between-individual variability on comparability assessment because of the simultaneous crossover design.
Animal T2001 exhibited an accelerated concentration decline after 14 days (Fig. 2) , which is typically seen when ADA develops although, in this case, ADA was not specifically determined in this study. Should this happen under a parallel or conventional crossover study design, the between-individual or between-period variability likely would impair or prevent the comparability assessment. Inclusion of the animal in the analysis did not markedly worsen the outcome, which exemplified the advantage of the study design enabled by the analytical method. Additionally, the impact of ADA on PK could be evaluated for both test and reference articles simultaneously in the same animal(s) which is also advantageous.
Current practice for a conventional PK biocomparability study for mAbs, regardless of study design, is to quantify the totality of a mixture of molecular species, for example, those with different forms of glycosylation. Small differences in PK for particular molecular species in the mixture are not able to be differentiated using a conventional immunoassay approach. The new analytical method allows for the monitoring of individual molecular species by their unique molecular signatures in a profile in vivo.
The study design supported by the innovative analytical m e t h o d e ff e c t i v e l y a d d r e s s e s t h e n e e d s of P K biocomparability assessment for mAb manufactured from different cell lines, and may be extended to other protein therapeutics with detectable differences of molecular signatures, such as different glycosylation patterns. The method is not applicable to those biotherapeutics with molecular signatures unaltered such as after a simple formulation change.
The application of the innovative analytical method with this new study design was proven successful in animals as reported in this brief technical note. This approach will need to be further validated in a small clinical PK biocomparability study. Its application to the clinical setting could bring a dramatic change in our current thinking on how to conduct PK biocomparability studies for biotherapeutics. In addition to the ethical improvement of using less numbers of subjects and related cost savings, the scientific advantages of this approach are obvious. 
